Supernus Pharmaceuticals Inc (FRA:S49)
€ 34.6 0.6 (1.76%) Market Cap: 1.97 Bil Enterprise Value: 1.62 Bil PE Ratio: 34.78 PB Ratio: 2.04 GF Score: 80/100

Supernus Pharmaceuticals Inc Acquisition of Adamas Pharmaceuticals Inc - M&A Call Transcript

Oct 11, 2021 / 12:30PM GMT
Release Date Price: €22.6 (-2.59%)
Operator

Good morning, and welcome to Supernus Pharmaceutical Business Update Conference Call. (Operator Instructions) As a reminder, this conference is being recorded. I would like to turn the conference over to Peter Vozzo of Westwicke Investor Relations, representative of Supernus Pharmaceuticals. You may begin.

Peter Vozzo
Westwicke Partners, LLC - MD

Thank you, Michelle. Good morning, everyone, and thank you for joining us today as we discuss the acquisition of Adamas Pharmaceuticals, which was announced this morning. On the call with me today are Supernus' Chief Executive Officer, Jack Khattar; Chief Financial Officer, Tim Dec; and Senior Vice President of Corporate Development, Bryan Roecklein. Today's call is being made available via the Investor Relations section of the company's website at ir.supernus.com. Following remarks by management, we will open the call to questions.

During the course of this call, management may make certain forward-looking statements regarding future events and the company's future performance. These forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot